US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ProShares Ultra Nasdaq Biotechnology

110.98

+5.965.68%

Post-market: 110.90-0.0800-0.07%19:30 EDT

Volume:7K

Turnover:815.79K

Market Cap:93.22M

PE:- -

High:111.36

Open:107.65

Low:106.78

Close:105.02

52wk High:126.40

52wk Low:62.72

Shares:840.00K

Float Shares:840.00K

Volume Ratio:0.77

T/O Rate:0.89%

Dividend:0.22

Dividend Rate:0.20%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Amgen Shares up 3% After Co's Autoimmune Disease Drug Succeeds in Late-Stage Trial

THOMSON REUTERS

Amgen Says Phase 3 Trial Shows Dazodalibep Cuts Systemic Disease Activity in Sjögren’s Disease

Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria

Amgen Announces Positive Topline Phase 3 Results for Dazodalibep in Moderate-to-Severe Systemic SjÖGren's Disease

THOMSON REUTERS

Amgen: Dazodalibep Showed Statistically Significant & Clinically Meaningful Improvement in Systemic Disease Activity

THOMSON REUTERS

Amgen: Phase 3 Oasiz 303 Study of Dazodalibep in Moderate-to-Severe Symptomatic SjÖGren’s Disease Expected to Complete in Q4 2026

THOMSON REUTERS

Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial

MT Newswires Live

Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study

Vertex Says Phase 2b Amplified Study Shows Inaxaplin Cuts Proteinuria in APOL1-Mediated Kidney Disease Patients with Modest Proteinuria

Vertex Pharmaceuticals Incorporated - Inaxaplin Reduces Uacr by -42.7% at Week 13 in Amkd with Modest Proteinuria

THOMSON REUTERS

Vertex Pharmaceuticals Incorporated - Inaxaplin Generally Safe and Well Tolerated in Both Amkd Cohorts

THOMSON REUTERS

Vertex Announces Positive Results from Phase 2B Amplified Study of Inaxaplin in Additional Populations of People with Apol1-Mediated Kidney Disease (Amkd) and Completion of Enrollment in the Phase 2/3 Amplitude Trial

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA)

Sino Biopharmaceutical Stock Slips 1.4% in Hong Kong, Underperforms Competitors

Moderna Inc. Stock Climbs 12.3%, Outperforms Peers

Vertex Pharmaceuticals Incorporated : Leerink Partners Resumes Coverage with Outperform Rating; Target Price $594

THOMSON REUTERS

Sino Biopharmaceutical Stock Rises 8.2% in Hong Kong, Outperforms Competitors

Correction to Vertex Material Listing Article on Sept. 17

Amgen Inc. Stock Outperforms Competitors on Strong Trading Day

Vertex wins approval for 24/7 underground operations at Reward Gold Mine

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/BIB/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIB\",,,,,undefined,":{"symbol":"BIB","market":"US","secType":"STK","nameCN":"ProShares Ultra Nasdaq Biotechnology","latestPrice":110.98,"timestamp":1791576000000,"preClose":105.0194,"halted":0,"volume":7447,"hourTrading":{"tag":"盘后","latestPrice":110.9,"preClose":110.98,"latestTime":"19:30 EDT","volume":60,"amount":6578.75,"timestamp":1791588606676,"change":-0.08,"changeRate":-0.000721,"amplitude":0},"delay":0,"changeRate":0.05675713249171105,"floatShares":840000,"shares":840000,"eps":0,"marketStatus":"Market Closed","change":5.9606,"latestTime":"10-09 16:00:00 EDT","open":107.654,"high":111.36,"low":106.78,"amount":815789.099235,"amplitude":0.043611,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":105.0194,"sharesOutstanding":1040000,"nav":105.0876,"aum":88273584,"dividendRate":0.001987,"bidAskSpread":0.003229,"postHourTrading":{"tag":"盘后","latestPrice":110.9,"preClose":110.98,"latestTime":"19:30 EDT","volume":60,"amount":6578.75,"timestamp":1791588606676,"change":-0.08,"changeRate":-0.000721,"amplitude":0},"volumeRatio":0.7671467199294564,"impliedVol":0.6489,"impliedVolPercentile":0.996},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIB\",,,,,undefined,":{"symbol":"BIB","floatShares":840000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7671467199294564,"shares":840000,"dividePrice":0.2205,"high":111.36,"amplitude":0.043611,"preClose":105.0194,"low":106.78,"week52Low":62.72,"pbRate":"--","week52High":126.399,"institutionHeld":0,"latestPrice":110.98,"eps":0,"divideRate":0.001987,"volume":7447,"delay":0,"ttmEps":0,"open":107.654,"prevYearClose":79.7794,"prevWeekClose":109.8002,"prevMonthClose":115.4524,"prevQuarterClose":115.4524,"fiveDayClose":109.8002,"twentyDayClose":109.7741,"sixtyDayClose":99.7552},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BIB\",params:#limit:5,,,undefined,":[{"date":"2026-09-23","symbol":"BIB","amount":0.082554,"announcedDate":"2026-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-23","defaultRemindTime":1790170200000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-29","payableDate":"2026-09-23","currency":"USD","dateTimestamp":1790136000000,"payDate":"2026-09-29"},{"date":"2026-03-25","symbol":"BIB","amount":0.00714,"announcedDate":"2026-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-25","defaultRemindTime":1774445400000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-31","payableDate":"2026-03-25","currency":"USD","dateTimestamp":1774411200000,"payDate":"2026-03-31"},{"date":"2025-12-24","symbol":"BIB","amount":0.134637,"announcedDate":"2025-12-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-24","defaultRemindTime":1766586600000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-31","payableDate":"2025-12-24","currency":"USD","dateTimestamp":1766552400000,"payDate":"2025-12-31"},{"date":"2025-09-24","symbol":"BIB","amount":0.180541,"announcedDate":"2025-09-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-24","defaultRemindTime":1758720600000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-24","currency":"USD","dateTimestamp":1758686400000,"payDate":"2025-09-30"},{"date":"2025-06-25","symbol":"BIB","amount":0.170576,"announcedDate":"2025-06-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-25","defaultRemindTime":1750858200000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-25","currency":"USD","dateTimestamp":1750824000000,"payDate":"2025-07-01"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BIB\",market:\"US\",,,undefined,":[{"executeDate":"2022-12-22","recordDate":"2022-12-23","paymentDate":"2022-12-30","value":0.019852,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-28","value":0.038393,"currency":"USD"},{"executeDate":"2024-03-20","recordDate":"2024-03-21","paymentDate":"2024-03-27","value":0.040324,"currency":"USD"},{"executeDate":"2024-06-26","recordDate":"2024-06-26","paymentDate":"2024-07-03","value":0.26476,"currency":"USD"},{"executeDate":"2024-09-25","recordDate":"2024-09-25","paymentDate":"2024-10-02","value":0.15285,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BIB\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669147177","title":"Amgen Shares up 3% After Co's Autoimmune Disease Drug Succeeds in Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669147177","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669147177?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:36","pubTimestamp":1790084178,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nL4N45E0VV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TBXU","AMGN","BBH","IBBQ","BK4585","LU1061106388.HKD","LU0058720904.USD","LU2112291526.USD","LU2242652126.USD","LU0109394709.USD","LU2468319806.SGD","IE00B4R5TH58.HKD","LU2089984988.USD","IE00BJJMRZ35.SGD","BK4139","IE00B2B36J28.USD","LU0868494617.USD","PBE","BK4588","IE0009355771.USD","BK4581","LU0889565916.HKD","IE00BJT1NW94.SGD","SG9999001440.SGD","BIB","LU0289739699.SGD","IBB","LU1571399168.USD","BK4533","LU1057294990.SGD","BK4599","BK4566","LU0320765992.SGD","LU1023059063.AUD","LU1983299246.USD","LU2242646821.SGD","BK4534","IE00BFTCPJ56.SGD","LU0122379950.USD","PJP","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669414223","title":"Amgen Says Phase 3 Trial Shows Dazodalibep Cuts Systemic Disease Activity in Sjögren’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2669414223","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669414223?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:04","pubTimestamp":1790082271,"startTime":"0","endTime":"0","summary":"Amgen says Phase 3 trial shows dazodalibep cuts systemic disease activity in Sjgren’s diseaseAmgen reported positive topline Phase 3 results for dazodalibep in adults with moderate-to-severe systemic ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL63L4Jz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0058720904.USD","BK4566","LU2242646821.SGD","IE00B4R5TH58.HKD","LU0320765992.SGD","LU0109394709.USD","IBB","SG9999001440.SGD","BK4139","AMGN","BK4581","LU1023059063.AUD","IE0002141913.USD","IE00BJT1NW94.SGD","LU2468319806.SGD","LU2112291526.USD","TBXU","BK4533","LU0868494617.USD","LU2089984988.USD","LU1571399168.USD","IBBQ","LU0122379950.USD","BIB","IE00BFTCPJ56.SGD","BK4534","BK4599","LU0289739699.SGD","IE0009355771.USD","PJP","BK4588","IE00B2B36J28.USD","LU1061106388.HKD","PBE","BBH","BK4585","LU1057294990.SGD","LU2242652126.USD","LU1983299246.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142464","title":"Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142464","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142464?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:02","pubTimestamp":1790082154,"startTime":"0","endTime":"0","summary":"Sept 22 (Reuters) - Vertex Pharmaceuticals Incorporated::*VERTEX ANNOUNCES POSITIVE RESULTS FROM PHASE 2B AMPLIFIED STUDY OF INAXAPLIN IN ADDITIONAL POPULATIONS OF PEOPLE WITH APOL1-MEDIATED KIDNEY DI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nRSD66vtCD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999013999.USD","IE00B4R5TH58.HKD","BK4139","LU0289739699.SGD","BBH","LU0417517546.SGD","LU0256863811.USD","IE00B19Z9Z06.USD","LU0079474960.USD","IE00B894F039.SGD","PBE","SG9999001176.SGD","IDNA","IBBQ","LU2089984988.USD","LU0889565916.HKD","LU1674673691.USD","IE00BJT1NW94.SGD","BIB","IE00BZ9MQY76.HKD","LU1093756325.SGD","LU2362541513.USD","LU2417539215.USD","BK4588","IE00B19Z3B42.SGD","LU2468319806.SGD","LU1035775433.USD","LU0432979614.USD","BK4532","IE0002141913.USD","GNMX","IE00B19Z9P08.USD","BK4567","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","TBXU","BK4533","LU0320765992.SGD","LU1093756168.USD","IBB","IE0009355771.USD","LU0061475181.USD","VRTX","LU2362541273.HKD","LU0234570918.USD","BK4585","LU0823416689.USD","LU2362540622.SGD","LU2236285917.USD","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142967","title":"Amgen Announces Positive Topline Phase 3 Results for Dazodalibep in Moderate-to-Severe Systemic SjÖGren's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142967","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142967?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082029,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nFWN45E0FE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","SG9999001440.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU2089984988.USD","LU2242652126.USD","BK4566","LU0868494617.USD","BBH","LU1571399168.USD","BK4599","IE00BFTCPJ56.SGD","BIB","LU1983299246.USD","LU2112291526.USD","IBB","BK4585","BK4534","LU0058720904.USD","IE0002141913.USD","BK4533","BK4588","BK4581","LU0289739699.SGD","LU1061106388.HKD","IE00B4R5TH58.HKD","AMGN","IE0009355771.USD","LU0109394709.USD","LU0122379950.USD","LU2468319806.SGD","BK4139","LU1057294990.SGD","PJP","LU2242646821.SGD","TBXU","PBE","IBBQ","IE00BJT1NW94.SGD","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142945","title":"Amgen: Dazodalibep Showed Statistically Significant & Clinically Meaningful Improvement in Systemic Disease Activity","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142945","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142945?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nP8N3Z20GZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1571399168.USD","TBXU","IE00B4R5TH58.HKD","LU1061106388.HKD","IE0009355771.USD","LU2468319806.SGD","LU1057294990.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00B2B36J28.USD","LU0122379950.USD","LU0889565916.HKD","LU2242652126.USD","BK4534","LU1023059063.AUD","LU0868494617.USD","PBE","BK4588","AMGN","BK4581","IBBQ","LU2112291526.USD","SG9999001440.SGD","LU0320765992.SGD","LU0058720904.USD","PJP","BIB","LU1983299246.USD","IE00BJJMRZ35.SGD","BK4566","BK4139","LU0109394709.USD","BK4533","BBH","IE00BFTCPJ56.SGD","BK4599","LU0289739699.SGD","BK4585","IBB","LU2242646821.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142617","title":"Amgen: Phase 3 Oasiz 303 Study of Dazodalibep in Moderate-to-Severe Symptomatic SjÖGren’s Disease Expected to Complete in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142617","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142617?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nP8N3Z20GZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BIB","LU2468319806.SGD","BK4534","AMGN","LU0122379950.USD","TBXU","LU0320765992.SGD","LU2089984988.USD","BK4581","BK4139","IE00BFTCPJ56.SGD","BK4566","BK4599","LU2242646821.SGD","LU2112291526.USD","LU0058720904.USD","BK4585","LU1057294990.SGD","BBH","LU1061106388.HKD","LU0889565916.HKD","LU0868494617.USD","IBBQ","IE00B4R5TH58.HKD","LU2242652126.USD","IE00BJT1NW94.SGD","PJP","IE00BJJMRZ35.SGD","LU1983299246.USD","LU0109394709.USD","PBE","IE00B2B36J28.USD","BK4533","IBB","IE0002141913.USD","LU0289739699.SGD","SG9999001440.SGD","LU1023059063.AUD","LU1571399168.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669425861","title":"Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669425861","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669425861?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:50","pubTimestamp":1790081406,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals  said Tuesday that a phase 2b study of inaxaplin to treat patients with APOL1-mediated kidney disease showed a 42.7% protein reduction, and a 17.3% reduction in patients who also have type 2 diabetes.The company said the drug showed a favorable safety profile with no drug-related serious adverse events reported. It said headaches were the most frequent side effect, which affected 7.3% of trial participants.The company said the reduction was measured after 13 weeks of treatment. Vertex said it has finished enrolling patients in a larger Phase 2/3 trial of inaxaplin.Shares of Vertex were up 2.2% pre-bell.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2324357040.USD","IBBQ","TBXU","IE00B19Z9P08.USD","LU0757428866.USD","IE0002141913.USD","BK4532","PBE","IE00BJT1NW94.SGD","BK4533","IDNA","LU0566484027.USD","VRTX","BBH","LU1674673428.USD","LU2236285917.USD","BK4567","LU0061475181.USD","LU1035775433.USD","LU1069344957.HKD","LU2362541513.USD","LU1778281490.HKD","SG9999001176.USD","LU1093756325.SGD","LU0058720904.USD","IBB","LU2089984988.USD","LU0079474960.USD","LU2468319806.SGD","IE00B19Z3581.USD","LU2417539215.USD","BIB","BK4023","IE00BJJMRZ35.SGD","BK4588","LU2362540622.SGD","SG9999013999.USD","LU1559883803.SGD","LU1674673691.USD","BK4139","IE0002270589.USD","LU1815336091.USD","IE00B894F039.SGD","IE00B19Z9Z06.USD","GNMX","SG9999001176.SGD","SGXZ57979304.SGD","IE0009355771.USD","IE00BZ9MQY76.HKD","VERX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669144313","title":"Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study","url":"https://stock-news.laohu8.com/highlight/detail?id=2669144313","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669144313?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:15","pubTimestamp":1790079331,"startTime":"0","endTime":"0","summary":"The company states: “Vertex Pharmaceuticals (VRTX) announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-announces-positive-results-from-phase-2b-inaxaplin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-announces-positive-results-from-phase-2b-inaxaplin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBBQ","TBXU","IE00B19Z9P08.USD","LU0757428866.USD","LU0823416689.USD","IE0002141913.USD","BK4532","PBE","LU1585245621.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","IDNA","VRTX","BBH","LU1674673428.USD","LU2236285917.USD","BK4567","LU2462157665.USD","LU0061475181.USD","LU0109394709.USD","LU1035775433.USD","LU0234570918.USD","LU1778281490.HKD","IE00B2B36J28.USD","LU1093756325.SGD","LU0256863811.USD","IBB","LU2089984988.USD","IE00B19Z3581.USD","LU1430594728.SGD","BIB","BK4023","LU0432979614.USD","LU1093756168.USD","BK4588","LU2362540622.SGD","SG9999013999.USD","LU0289739699.SGD","IE00BFTCPJ56.SGD","LU1674673691.USD","BK4139","IE00B4R5TH58.HKD","LU1815336091.USD","IE00B19Z9Z06.USD","GNMX","SG9999001176.SGD","LU2237438978.USD","IE0009355771.USD","IE00B19Z3B42.SGD","VERX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669177141","title":"Vertex Says Phase 2b Amplified Study Shows Inaxaplin Cuts Proteinuria in APOL1-Mediated Kidney Disease Patients with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669177141","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669177141?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:02","pubTimestamp":1790078577,"startTime":"0","endTime":"0","summary":"Vertex says Phase 2b AMPLIFIED study shows inaxaplin cuts proteinuria in APOL1-mediated kidney disease patients with modest proteinuriaVertex reported positive Phase 2b AMPLIFIED results for inaxaplin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL8CHhBr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","LU1069344957.HKD","LU2462157665.USD","IDNA","LU1035775433.USD","IE0009355771.USD","LU2468319806.SGD","LU2324357040.USD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00B2B36J28.USD","LU1093756325.SGD","LU1674673428.USD","LU0889565916.HKD","GNMX","LU1674673691.USD","LU0256863811.USD","LU0061475181.USD","BK4532","PBE","SG9999001176.SGD","BK4588","BK4567","LU2362541513.USD","IBBQ","LU2237438978.USD","IE00BZ9MQY76.HKD","LU1093756168.USD","IE00B19Z3B42.SGD","LU0320765992.SGD","LU0058720904.USD","BIB","IE00B19Z9P08.USD","SG9999013999.USD","IE00B19Z9Z06.USD","LU0079474960.USD","BK4139","LU2362541273.HKD","LU0109394709.USD","IE0002270589.USD","VRTX","BBH","LU0432979614.USD","IE00BFTCPJ56.SGD","LU0823416689.USD","IE00B19Z3581.USD","BK4585","IBB","LU2089984988.USD","SGXZ57979304.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669419861","title":"Vertex Pharmaceuticals Incorporated - Inaxaplin Reduces Uacr by -42.7% at Week 13 in Amkd with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669419861","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669419861?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2237438978.USD","LU2468319806.SGD","LU1069344957.HKD","GNMX","VRTX","IE00B19Z9Z06.USD","IE00B894F039.SGD","LU1778281490.HKD","IE00B19Z9P08.USD","IE0002270589.USD","LU2456880835.USD","IBBQ","IE0009355771.USD","LU1430594728.SGD","LU1585245621.USD","PBE","IE00BJT1NW94.SGD","LU2462157665.USD","IBB","LU0823416689.USD","IE00BJJMRZ35.SGD","LU0079474960.USD","LU2236285917.USD","SG9999001176.SGD","LU0109394709.USD","BK4139","BK4585","LU0234570918.USD","LU2417539215.USD","IDNA","LU1674673428.USD","LU0889565916.HKD","IE00B19Z3581.USD","IE00B2B36J28.USD","LU2362541513.USD","LU1674673691.USD","LU2324357040.USD","LU1093756325.SGD","LU2362541273.HKD","LU0417517546.SGD","IE00B4R5TH58.HKD","LU2362540622.SGD","SGXZ57979304.SGD","LU0256863811.USD","LU0289739699.SGD","BIB","TBXU","BBH","LU1093756168.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669419041","title":"Vertex Pharmaceuticals Incorporated - Inaxaplin Generally Safe and Well Tolerated in Both Amkd Cohorts","url":"https://stock-news.laohu8.com/highlight/detail?id=2669419041","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669419041?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1585245621.USD","BK4139","LU0889565916.HKD","LU2417539215.USD","SG9999001176.SGD","BBH","BK4588","LU0109394709.USD","IE0002270589.USD","VRTX","BK4585","LU0079474960.USD","LU2456880835.USD","GNMX","IBB","LU2362541513.USD","LU0256863811.USD","BIB","LU0234570918.USD","SG9999001176.USD","BK4533","SG9999013999.USD","IE00B19Z9P08.USD","TBXU","IBBQ","LU0061475181.USD","LU2462157665.USD","IDNA","LU2237438978.USD","BK4567","IE0002141913.USD","LU0058720904.USD","LU0432979614.USD","IE00B19Z9Z06.USD","BK4532","LU1674673428.USD","IE00BZ9MQY76.HKD","LU0320765992.SGD","IE00BJT1NW94.SGD","LU1093756325.SGD","LU1778281490.HKD","SGXZ57979304.SGD","LU2324357040.USD","LU2089984988.USD","LU2362541273.HKD","PBE","IE00BJJMRZ35.SGD","LU1035775433.USD","LU1069344957.HKD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669141954","title":"Vertex Announces Positive Results from Phase 2B Amplified Study of Inaxaplin in Additional Populations of People with Apol1-Mediated Kidney Disease (Amkd) and Completion of Enrollment in the Phase 2/3 Amplitude Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669141954","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669141954?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGXZ57979304.SGD","SG9999001176.USD","PBE","LU2089984988.USD","LU0061475181.USD","LU0079474960.USD","IE00B2B36J28.USD","SG9999013999.USD","BK4139","IE00B19Z3581.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","LU1674673428.USD","BIB","LU1035775433.USD","LU1585245621.USD","LU2237438978.USD","IBB","BK4567","LU0417517546.SGD","LU0058720904.USD","IE0002141913.USD","LU0289739699.SGD","LU1674673691.USD","IE0002270589.USD","BBH","GNMX","IE00BZ9MQY76.HKD","LU0823416689.USD","BK4585","IDNA","LU0432979614.USD","LU1778281490.HKD","LU1069344957.HKD","LU0109394709.USD","LU0889565916.HKD","LU2236285917.USD","BK4533","LU2456880835.USD","TBXU","SG9999001176.SGD","VRTX","IBBQ","BK4532","LU1093756325.SGD","IE00B19Z9P08.USD","IE00BJT1NW94.SGD","LU0234570918.USD","IE00B19Z3B42.SGD","LU0256863811.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669143096","title":"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669143096","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669143096?lang=en_us&edition=fundamental","pubTime":"2026-09-22 18:10","pubTimestamp":1790071809,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA). ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-invivyd-ivvd-and-humacyte-huma-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-invivyd-ivvd-and-humacyte-huma-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIB","LU0889565916.HKD","IE00B4R5TH58.HKD","LU1023059063.AUD","BK4139","LU0122379950.USD","IE0002141913.USD","PBE","LU2468319806.SGD","BK4539","HCSG","IE00BFTCPJ56.SGD","LU0289739699.SGD","LABU","BK4599","LU0128526141.USD","IE00BJJMRZ35.SGD","BK4137","LU0868494617.USD","LU1061106388.HKD","IE00B2B36J28.USD","LU2242646821.SGD","LU0058720904.USD","LU1057294990.SGD","LU1571399168.USD","XBI","PJP","LU2242652126.USD","BK4588","IE0009355771.USD","XLV","IVVD","LU1983299246.USD","LU0320765992.SGD","BK4533","BK4563","SG9999001440.SGD","LU2089984988.USD","BBH","HUMA","AMGN","IBBQ","LU0029874061.USD","LU0109394709.USD","BK4566","IBB","BK4585","TBXU","IE00BJT1NW94.SGD","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669511784","title":"Sino Biopharmaceutical Stock Slips 1.4% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2669511784","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669511784?lang=en_us&edition=fundamental","pubTime":"2026-09-22 16:32","pubTimestamp":1790065920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. slipped 1.4% to 5.84 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.2% to 25087.75.Sino Biopharmaceutical Ltd. closed 32% short of its 52-week high of HK$8.56, which the company reached Sept. 23.The stock underperformed when compared to some of its competitors, as CSPC Pharmaceutical Group Ltd. rose 1.1% and Amgen Inc. remained unchanged.Trading volume totaled 87.2 million shares, compared to the 50-day average of 88.8 million shares.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU2242646821.SGD","IE00BFTCPJ56.SGD","BK4599","LU2242652126.USD","LU2468319806.SGD","SG9999001440.SGD","LU2112291526.USD","BIB","BBH","BK1191","LU1023059063.AUD","BK4585","PBE","LU1983299246.USD","BK4139","PJP","AMGN","LU0889565916.HKD","LU1571399168.USD","BK1515","IE00BJT1NW94.SGD","LU1057294990.SGD","IE0009355771.USD","HK0000165453.HKD","IE0002141913.USD","IE00B2B36J28.USD","TBXU","IBB","IE00B4R5TH58.HKD","01177","IBBQ","BK4581","LU1061106388.HKD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","LU0122379950.USD","LU0320765992.SGD","BK4533","BK4534","BK4588","LU0289739699.SGD","LU2089984988.USD","IE00BZ08YT58.USD","BK1521","IE00BJJMRZ35.SGD","LU0868494617.USD","LU0058720904.USD","BK1589","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669619383","title":"Moderna Inc. Stock Climbs 12.3%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2669619383","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669619383?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:33","pubTimestamp":1790022780,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. jumped 12.3% to $172.94 on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index rising 2.3% to 27,122.09 and the Dow Jones Industrial Average rising 0.7% to 52,048.83.Moderna Inc. closed 2.1% short of its 52-week high of $176.66, which the company reached on August 19th.The stock outperformed some of its peers, as Johnson & Johnson fell 0.2% to $269.47, Pfizer Inc. rose 0.3% to $27.74, and Gilead Sciences Inc. rose 0.30% to $150.56.Trading volume totaled 20.9 million, compared to the 50-day average of 17.9 million.Data source: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673428.USD","LU0889565916.HKD","LU0882574055.USD","IE00BSNM7G36.USD","LU0320765992.SGD","SG9999015952.SGD","BK4501","LU1066051498.USD","BK4578","LU2089984988.USD","LU1066053197.SGD","LU0234570918.USD","LU1430594728.SGD","BBH","LU0859254822.USD","LU1778281490.HKD","BIB","BMED","IE0002270589.USD","SG9999015986.USD","LU0861579265.USD","IBB","BK4534","LU0058720904.USD","BK4533","LU0289739699.SGD","LU1061106388.HKD","LGHT","IDNA","IE00B7SZLL34.SGD","LU0109394709.USD","LU0122379950.USD","MEDI","LU2468319806.SGD","BK4139","MRNX","LU1934455194.USD","TBXU","MRNA","BK4548","LU1839511570.USD","IBBQ","WDNA","MRNY","BK4532","LU0965509101.SGD","LU1023059063.AUD","TMED","GNOM","GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669315293","title":"Vertex Pharmaceuticals Incorporated : Leerink Partners Resumes Coverage with Outperform Rating; Target Price $594","url":"https://stock-news.laohu8.com/highlight/detail?id=2669315293","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669315293?lang=en_us&edition=fundamental","pubTime":"2026-09-21 18:03","pubTimestamp":1789985027,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45A0U1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2324357040.USD","BK4588","BK4139","IE00B19Z3581.USD","IE00B4R5TH58.HKD","SG9999001176.SGD","LU2362541513.USD","LU1093756325.SGD","IE00B19Z9P08.USD","LU0109394709.USD","LU1674673428.USD","BIB","LU0823416689.USD","VRTX","GNMX","LU2089984988.USD","IE00BJT1NW94.SGD","IE00B894F039.SGD","TBXU","LU1778281490.HKD","LU2417539215.USD","LU0320765992.SGD","BK4533","IE0009355771.USD","LU1585245621.USD","LU2362541273.HKD","LU2456880835.USD","IBB","LU2468319806.SGD","IE00BFTCPJ56.SGD","BBH","LU0061475181.USD","LU0289739699.SGD","LU2462157665.USD","LU2362540622.SGD","SG9999013999.USD","LU1035775433.USD","BK4567","LU0058720904.USD","LU0256863811.USD","BK4532","LU1069344957.HKD","LU1093756168.USD","LU2236285917.USD","IBBQ","PBE","IE00BJJMRZ35.SGD","LU0234570918.USD","IDNA","IE00BZ9MQY76.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669156720","title":"Sino Biopharmaceutical Stock Rises 8.2% in Hong Kong, Outperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2669156720","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669156720?lang=en_us&edition=fundamental","pubTime":"2026-09-21 16:30","pubTimestamp":1789979400,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. rallied 8.2% to 5.92 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.2% to 25042.71.Sino Biopharmaceutical Ltd. closed 32% below its 52-week high of HK$8.65, which the company achieved Sept. 22.The stock outperformed some of its competitors, as CSPC Pharmaceutical Group Ltd. rose 7.6% and Amgen Inc. remained unchanged.Trading volume totaled 150.2 million shares, compared to the 50-day average of 89.1 million shares.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU2242646821.SGD","IE00BFTCPJ56.SGD","BK4599","LU2242652126.USD","LU2468319806.SGD","SG9999001440.SGD","LU2112291526.USD","BIB","BBH","BK1191","LU1023059063.AUD","BK4585","PBE","LU1983299246.USD","BK4139","PJP","AMGN","LU0889565916.HKD","LU1571399168.USD","BK1515","IE00BJT1NW94.SGD","LU1057294990.SGD","IE0009355771.USD","HK0000165453.HKD","IE0002141913.USD","IE00B2B36J28.USD","TBXU","IBB","IE00B4R5TH58.HKD","01177","IBBQ","BK4581","LU1061106388.HKD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","LU0122379950.USD","LU0320765992.SGD","BK4533","BK4534","BK4588","LU0289739699.SGD","LU2089984988.USD","IE00BZ08YT58.USD","BK1521","IE00BJJMRZ35.SGD","LU0868494617.USD","LU0058720904.USD","BK1589","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669412132","title":"Correction to Vertex Material Listing Article on Sept. 17","url":"https://stock-news.laohu8.com/highlight/detail?id=2669412132","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669412132?lang=en_us&edition=fundamental","pubTime":"2026-09-21 12:48","pubTimestamp":1789966080,"startTime":"0","endTime":"0","summary":"Tan Chin Teong is the founder and technical director of Vertex Material. \"Malaysia's Vertex Material Sets Sights on 2027 U.S. Listing,\" at 0931 GMT on Sept. 17, misstated the name as Tan Chin Tong.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9Z06.USD","PBE","LU1069344957.HKD","SG9999013999.USD","IE00BJJMRZ35.SGD","IDNA","VRTX","BIB","LU0320765992.SGD","IE00B894F039.SGD","GNMX","LU2362541273.HKD","LU2468319806.SGD","IE00B19Z9P08.USD","BBH","LU2362540622.SGD","LU0109394709.USD","LU0566484027.USD","LU1585245621.USD","LU2362541513.USD","LU2089984988.USD","LU0256863811.USD","LU0823416689.USD","IE00B4R5TH58.HKD","SGXZ57979304.SGD","LU2324357040.USD","SG9999001176.SGD","IE00BFTCPJ56.SGD","BK4567","IE00B19Z3B42.SGD","LU0079474960.USD","LU1093756168.USD","VERX","IE00B2B36J28.USD","LU1093756325.SGD","LU0234570918.USD","LU2462157665.USD","LU0417517546.SGD","BK4023","LU2236285917.USD","IBB","LU0889565916.HKD","SG9999001176.USD","TBXU","BK4588","LU0058720904.USD","LU0757428866.USD","LU1778281490.HKD","LU1035775433.USD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668973164","title":"Amgen Inc. Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2668973164","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668973164?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:34","pubTimestamp":1789763640,"startTime":"0","endTime":"0","summary":"DJ Amgen Inc. Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Amgen Inc.  rallied 1.55% to $385.65 Friday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index  rising 0.17% to 7,650.50 and the Dow Jones Industrial Average  falling 0.18% to 51,682.64.This was the stock's third consecutive day of gains.Amgen Inc. closed 13.73% below its 52-week high of $447.03, which the company reached on August 25th.The stock outperformed some of its competitors Friday, as Johnson & Johnson  fell 0.09% to $269.99, Pfizer Inc.  rose 0.07% to $27.66, and AbbVie Inc.  fell 0.02% to $263.96.Trading volume  eclipsed its 50-day average volume of 2.6 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 18, 2026.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B2B36J28.USD","LU0889565916.HKD","LU0289739699.SGD","LU0868494617.USD","LU2112291526.USD","AMGN","LU1571399168.USD","BBH","BK4588","LU0109394709.USD","LU2242646821.SGD","LU2242652126.USD","LU2468319806.SGD","LU1023059063.AUD","BK4585","04332","LU0122379950.USD","LU1983299246.USD","IBB","PJP","BIB","BK4533","TBXU","IBBQ","LU1057294990.SGD","BK4581","IE0009355771.USD","IE0002141913.USD","LU0058720904.USD","LU1061106388.HKD","LU0320765992.SGD","SG9999001440.SGD","IE00BJT1NW94.SGD","BK4534","LU2089984988.USD","PBE","IE00BJJMRZ35.SGD","BK4566","BK4599","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668914913","title":"Vertex wins approval for 24/7 underground operations at Reward Gold Mine","url":"https://stock-news.laohu8.com/highlight/detail?id=2668914913","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668914913?lang=en_us&edition=fundamental","pubTime":"2026-09-18 08:18","pubTimestamp":1789690694,"startTime":"0","endTime":"0","summary":"An announcement from Vertex Minerals Ltd. ( ($AU:VTX) ) is now available. Vertex Minerals has secured a varied Environment Protection License from ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vertex-wins-approval-for-24-7-underground-operations-at-reward-gold-mine?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vertex-wins-approval-for-24-7-underground-operations-at-reward-gold-mine?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","LU2324357040.USD","LU0432979614.USD","LU0058720904.USD","BK4532","LU2362540622.SGD","IE0002270589.USD","SG9999001176.USD","LU1430594728.SGD","VERX","LU0109394709.USD","IBB","BK4139","LU0079474960.USD","IDNA","SG9999001176.SGD","IE0002141913.USD","IE00BJT1NW94.SGD","LU2468319806.SGD","LU1815336091.USD","TBXU","BK4533","LU2089984988.USD","VRTX","LU2236285917.USD","IBBQ","LU1035775433.USD","BK4567","IE00B894F039.SGD","BIB","GNMX","IE00BFTCPJ56.SGD","LU0757428866.USD","SGXZ57979304.SGD","IE00BZ9MQY76.HKD","LU0289739699.SGD","IE0009355771.USD","LU2362541513.USD","LU1674673691.USD","IE00B19Z9Z06.USD","LU1069344957.HKD","LU1559883803.SGD","IE00B19Z9P08.USD","PBE","LU1778281490.HKD","BBH","BK4585","LU2462157665.USD","SG9999013999.USD","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}